Structure of the Sulfoxide Synthase EgtB from the Ergothioneine Biosynthetic Pathway K. V. Goncharenko, A. Vit, W. Blankenfeldt*, and F. P. Seebeck*, Angew. Chem. Int. Ed. 2015 , 54, 2821 . University of Basel Ergothioneine occurs in a broad range of prokaryotic and eukaryotic organisms, including humans and human pathogens such as Mycobacterium tuberculosis. The precise cellular function of ergothioneine is not known, but recent observations suggest that this sulfur compound may be a protectant against oxidative stress. To elucidate the structural basis for sulfoxide synthase activity, Seebeck, Blankenfeldt and coworkers have endeavoured and successfully achieved the crystal structure of EgtB from Mycobacterium thermoresistibile in complex with γ-glutamyl cysteine and N-α-trimethyl histidine. The study reveals that the two substrates and three histidine residues serve as ligands in an octahedral iron binding site. This active site geometry is consistent with a catalytic mechanism in which C-S bond formation is initiated by an iron(iii)-complexed thiyl radical attacking the imidazole ring of N-α-trimethyl histidine. However, the technology has been limited by difficulties in the decoding process. Scheuermann, Neri and coworkers now report a strategy that overcomes this limitation. Small organic molecules were conjugated to complementary DNA strands that contain a unique identifying code. DNA hybridization followed by an inter-strand code-transfer created a DNA-encoded chemical library of 111,100 members (see illustration; with permission, NPG). Using this approach, a low micromolar binder to alpha-1-acid glycoprotein and a ligand to carbonic anhydrase IX has been identified, which dramatically improved tumour targeting performance in vivo. Nat. Med. 2015, 21, 270 . University of Bern Systemic use of antisense oligonucleotides (AONs) is limited due to poor tissue uptake. Garcia, Leumann and collaborators present a new class of AONs made of tricyclo-DNA (tcDNA), which displays unique pharmacological properties and unprecedented uptake by many tissues after systemic administration. Improved properties were demonstrated in mouse models of Duchenne muscular dystrophy (DMD), a neurogenetic disease in the dystrophin gene. The findings render tcDNA-AON chemistry particularly attractive as a potential future therapy for patients with DMD and other neuromuscular disorders or with other diseases that are eligible for exons k i p p i n g approaches r e q u i r i n g whole-body treatment.
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